Aurinia Pharmaceuticals (NASDAQ:AUPH) Issues Earnings Results

Key Points

• Aurinia Pharmaceuticals exceeded quarterly expectations: The company reported EPS of $0.23 versus the $0.22 consensus estimate and revenue of $83.70 million, narrowly above expectations of $83.61 million.
• Shares fell 3.0% to $16.69 despite the earnings beat. Aurinia has a $2.22 billion market capitalization and trades near its 50-day moving average.
• Analyst sentiment remains positive but mixed, with a consensus “Moderate Buy” rating and an average price target of $17.75. Aurinia’s lead product, Lupkynis, is approved to treat adults with active lupus nephritis.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP released its quarterly earnings data on Friday. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.22 by $0.01, FiscalAI reports. Aurinia Pharmaceuticals had a net margin of 100.84% and a return on equity of 26.11%. The company had revenue of $83.70 million for the quarter, compared to analysts' expectations of $83.61 million.

Aurinia Pharmaceuticals Stock Down 3.0%

Shares of NASDAQ AUPH traded down $0.52 during midday trading on Friday, reaching $16.69. 477,576 shares of the company's stock traded hands, compared to its average volume of 1,146,767. The company has a market cap of $2.22 billion, a price-to-earnings ratio of 7.28 and a beta of 1.60. The stock's 50 day simple moving average is $16.50 and its 200-day simple moving average is $15.64. Aurinia Pharmaceuticals has a one year low of $12.07 and a one year high of $19.25. The company has a quick ratio of 4.97, a current ratio of 5.42 and a debt-to-equity ratio of 0.07.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on AUPH. Royal Bank Of Canada increased their price target on Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the company a "sector perform" rating in a research report on Friday, August 7th. Wall Street Zen lowered Aurinia Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 8th. Bloom Burton upgraded shares of Aurinia Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 20th. Weiss Ratings upgraded Aurinia Pharmaceuticals from a "buy (b-)" rating to a "buy (b)" rating in a research note on Thursday, October 22nd. Finally, Zacks Research downgraded shares of Aurinia Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, July 21st. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat.com, Aurinia Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $17.75.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company's principal product is Lupkynis (voclosporin), an oral calcineurin inhibitor used in combination with other immunosuppressive therapies to treat adults with active lupus nephritis, a serious kidney complication of systemic lupus erythematosus.

Voclosporin was approved by the U.S. Food and Drug Administration in 2021, making Lupkynis the first oral therapy specifically approved in the United States for adult patients with active lupus nephritis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.